The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis

SARS-CoV-2의 Delta 변종으로 인한 COVID-19에 대한 BNT162b2 mRNA 백신의 효과: 체계적인 검토 및 메타 분석

Published on
Journal: Inflammopharmacology
[저자] Chia Siang Chia Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
[Category] COVID19(2023년), SARS, 변종,
PMC URL    [DOI] 10.1007/s10787-021-00915-7    
[Article Type] Meta-Analysis
[Source] PMC

Abstract
Meta-analyses were utilized to determine the overall effectiveness of BNT162b2 mRNA vaccine (Pfizer vaccine) against COVID-19 caused by Delta variant from large real-world studies. A systematic literature search with no language restriction was performed in electronic databases to identify eligible observational studies that reported the effectiveness of the BNT162b2 mRNA vaccine to prevent reverse transcription-polymerase chain reaction (RT-PCR) confirmed COVID-19 caused by Delta variant of SARS-CoV-2 (B.1.617.2). Random-effects meta-analysis model was used to estimate the pooled odds ratio (OR) at a 95% confidence interval, and the vaccine effectiveness was indicated as (pooled OR – 1)/OR. Seven studies were included for this meta-analysis. The meta-analysis revealed that the administration of BNT162b2 mRNA vaccine protected against RT-PCR confirmed COVID-19 caused by Delta variant ≥ 21 days after the first dose, with vaccine effectiveness of 55% (95% confidence interval 46-63%), as well as ≥ 14 days after the second dose, with vaccine effectiveness of 81% (95% confidence interval 69-88%). In conclusion, the BNT162b2 mRNA vaccine offers a substantial protection rate against RT-PCR confirmed COVID-19 caused by the Delta variant upon full vaccination, albeit with slightly reduced effectiveness relative to other strains of SARS-CoV-2.
Keywords: BNT162b2; COVID-19; Delta; Vaccine; Variant.

All Keywords
【저자키워드】 COVID-19, Vaccine, variant, Delta, BNT162b2, 【초록키워드】 Meta-analysis, SARS-CoV-2, vaccination, mRNA vaccine, variant, B.1.617.2, delta variant, RT-PCR, database, observational studies, observational study, BNT162b2, Pfizer, polymerase chain reaction, Effectiveness, reverse transcription, BNT162b2 mRNA, BNT162b2 mRNA vaccine, Reverse transcription-polymerase chain reaction, administration, meta-analyses, Odds ratio, strain, Chain Reaction, Random-effects meta-analysis, 95% confidence interval, second dose, first dose, systematic literature search, offer, Prevent, meta-analysis model, identify, was used, caused, reported, indicated, was performed, reduced, determine, the vaccine, eligible, of BNT162b2, 【제목키워드】 systematic review, Effectiveness, caused, of BNT162b2,
{{{ 추상적인 }}} 대규모 실제 연구에서 델타 변이체로 인한 COVID-19에 대한 BNT162b2 mRNA 백신(화이자 백신)의 전반적인 효과를 결정하기 위해 메타 분석이 활용되었습니다. BNT162b2 mRNA 백신이 역전사 중합효소 연쇄 반응(RT-PCR)을 예방하는 효과를 보고한 적격한 관찰 연구를 확인하기 위해 언어 제한이 없는 체계적인 문헌 검색을 수행하여 SARS의 델타 변이체로 인한 COVID-19를 확인했습니다. -CoV-2(B.1.617.2). 무작위 효과 메타 분석 모델을 사용하여 95% 신뢰 구간에서 합동 오즈비(OR)를 추정하고 백신 효과를 (합동 OR - 1)/OR로 표시했습니다. 이 메타 분석을 위해 7개의 연구가 포함되었습니다. 메타 분석에 따르면 RT-PCR에 대해 보호된 BNT162b2 mRNA 백신의 투여는 첫 번째 접종 후 21일 이상 델타 변이체에 의한 COVID-19를 확인했으며 백신 효과는 55%(95% 신뢰 구간 46-63%), 두 번째 접종 후 14일 이상, 백신 효과는 81%(95% 신뢰 구간 69-88%)입니다. 결론적으로, BNT162b2 mRNA 백신은 다른 SARS-CoV-2 변종에 비해 효과가 약간 감소했지만 전체 백신 접종 시 Delta 변이체로 인한 RT-PCR로 확인된 COVID-19에 대해 상당한 보호율을 제공합니다. {{ 키워드: }} BNT162b2; 코로나바이러스감염증-19 : 코로나19; 델타; 백신; 변종.